Comparative Pharmacology
Head-to-head clinical analysis: LUCENTIS versus VABYSMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUCENTIS versus VABYSMO.
LUCENTIS vs VABYSMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits the biological activity of vascular endothelial growth factor A (VEGF-A), thereby preventing VEGF-A from interacting with its receptors (VEGFR1 and VEGFR2) on endothelial cells, reducing neovascularization and vascular permeability.
Vabysmo (faricimab) is a bispecific monoclonal antibody that binds to vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), inhibiting their activity. By blocking VEGF-A, it reduces endothelial cell proliferation, vascular permeability, and angiogenesis. By inhibiting Ang-2, it stabilizes blood vessels by enhancing pericyte coverage and reducing vascular leakage and inflammation.
Intravitreal injection of 0.5 mg (0.05 mL) once every 4 weeks (monthly).
Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL solution) once every 4 weeks (monthly) for 4 doses, then 6 mg every 8 weeks (2 months) thereafter.
None Documented
None Documented
Terminal elimination half-life from vitreous humor: approximately 9 days (range 7–11 days) in humans. From serum: ~0.5 days (due to rapid systemic clearance). Clinical context: supports monthly intravitreal dosing.
Terminal elimination half-life: approximately 26 days (range 20–36 days) in clinical studies. This supports dosing every 8–16 weeks for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Primarily metabolized via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible due to high molecular weight (48 kDa). Fecal/biliary elimination not characterized. Systemic clearance ~0.81 mL/hr.
Renal elimination: Vabysmo (faricimab) is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion data are available; renal elimination of intact antibody is minimal due to high molecular weight. Biliary/fecal excretion is not a major route.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor